Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with Febrile Neutropenia by Phillips, Robert S. et al.
Updated Systematic Review and Meta-Analysis of the
Performance of Risk Prediction Rules in Children and
Young People with Febrile Neutropenia
Robert S. Phillips
1*, Thomas Lehrnbecher
2, Sarah Alexander
3, Lillian Sung
3
1Centre for Reviews and Dissemination, University of York, York, United Kingdom, 2Department of Paediatric Haematology and Oncology, University of Frankfurt,
Frankfurt, Germany, 3Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
Abstract
Introduction: Febrile neutropenia is a common and potentially life-threatening complication of treatment for childhood
cancer, which has increasingly been subject to targeted treatment based on clinical risk stratification. Our previous meta-
analysis demonstrated 16 rules had been described and 2 of them subject to validation in more than one study. We aimed
to advance our knowledge of evidence on the discriminatory ability and predictive accuracy of such risk stratification clinical
decision rules (CDR) for children and young people with cancer by updating our systematic review.
Methods: The review was conducted in accordance with Centre for Reviews and Dissemination methods, searching multiple
electronic databases, using two independent reviewers, formal critical appraisal with QUADAS and meta-analysis with
random effects models where appropriate. It was registered with PROSPERO: CRD42011001685.
Results: We found 9 new publications describing a further 7 new CDR, and validations of 7 rules. Six CDR have now been
subject to testing across more than two data sets. Most validations demonstrated the rule to be less efficient than when
initially proposed; geographical differences appeared to be one explanation for this.
Conclusion: The use of clinical decision rules will require local validation before widespread use. Considerable uncertainty
remains over the most effective rule to use in each population, and an ongoing individual-patient-data meta-analysis should
develop and test a more reliable CDR to improve stratification and optimise therapy. Despite current challenges, we believe
it will be possible to define an internationally effective CDR to harmonise the treatment of children with febrile neutropenia.
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Introduction
Febrile neutropenia (FNP) is a common and potentially life-
threatening complication of therapy for childhood cancer, which
has increasingly been subject to targeted treatment based on
clinical risk stratification [1]. For children this move towards risk-
directed care is based upon evidence of the low incidence of death
[2], the majority of patients being without identified significant
infection or sepsis [3], and small randomised trials demonstrating
the feasibility of out-patient based treatment for patients at low-
risk of septic complications [4]. A large proportion of the evidence
for risk stratifications has originated from adult oncology [5] It is
acknowledged that children are not ‘little adults’ but distinct in the
biology of their malignancies, treatment regimens, infections and
psychosocial setting and therefore specific evidence for stratifica-
tion of children with FNP is needed [6].
Since we undertook a systematic review and meta-analysis of
risk stratification systems in 2008 [3], further studies have been
published which address this issue [7]. Accordingly we have
updated our review to summarise the most recent advances in our
knowledge of evidence on the discriminatory ability and predictive
accuracy of such risk stratification clinical decision rules (CDR) for
children and young people with cancer.
Methods
This update review was conducted in accordance with
‘‘Systematic reviews: CRD’s guidance for undertaking reviews in
health care’’ [8] and registered on the PROSPERO Registry of
systematic reviews: CRD42011001685. It sought studies which
aimed to derive or validate a CDR in children or young people
(aged 0–18 y) presenting with febrile neutropenia. Both prospec-
tive and retrospective cohorts were included, but those using a
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38300case-control (‘‘two-gate’’) approach were excluded as these have
been previously shown to exaggerate diagnostic accuracy estimates
[9].
Search strategy and selection criteria
The electronic search strategy [3] was reviewed and repeated on
the following databases from February 2009 to September 2011:
N MEDLINE
N MEDLINE In-Process & Other Non-Indexed Citations
N EMBASE
N CINAHL
N Literatura Latinoamericana y del Caribe en Ciencias de la
Salud (LILACS)
Reference lists of relevant systematic reviews and included
articles were reviewed for further relevant articles. Published and
unpublished studies were sought and no language restrictions
applied. Non-English language studies were translated. Two
reviewers independently screened the title and abstract of studies
for inclusion, and then the full text of retrieved articles.
Disagreements were resolved by consensus.
Validity assessment and data extraction
The validity of each study was assessed as with our previous
review using 11 of the 14 questions from the QUADAS assessment
tool for diagnostic accuracy studies [10].
Data were extracted by one reviewer and checked by the other.
The data extracted included age and sex distribution of the
included participants, geographical location of the study, the
participant inclusion/exclusion criteria, and the performance of
the CDR as a 2*k table (where k refers to the number of strata
described) or as sensitivity/specificity, as well as aspects of the
methods used to derive the CDR (where applicable).
Methods of analysis/synthesis
Where possible, data from new publications were added to
meta-analyses undertaken in the original review [3]. Quantitative
synthesis was undertaken when more than 2 studies tested the
same CDR, and where appropriate, was investigated for sources
for heterogeneity. For this update review, only dichotomous test
Figure 1. Flowchart of studies through the review.
doi:10.1371/journal.pone.0038300.g001
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was used (pooling sensitivity and specificity separately) [11]. For
those with 4 or more, a bivariate model was fitted using ‘metandi’
in STATA10 [12]. The protocol specified a random-effects meta-
analysis was undertaken using WinBUGS 1.4.3 [13] for tests with
3 or more risk strata, but no data were found eligible for this
analysis.
Heterogeneity between study results was explored through
consideration of study populations, study design, CDR and
outcomes chosen, although the small number of studies in each
category limited this approach. Sensitivity analysis was undertaken
by comparing results when the original (derivation) data set was
included and excluded.
For those areas where a quantitative synthesis was not possible,
a narrative approach was used.
Results
9 articles reporting on 8 studies were eligible for inclusion in the
review (see Figure 1). The studies included patients from 2 month
to 22 years old, with a wide range of malignancies, and a total of
2591 episodes of FNP describing four groups of outcomes: death,
critical care requirement, serious medical complication, and
bacteraemia. Six studies undertook prospective data collection,
two retrospective. Details of the CDR included in this review are
given in Table 1.
Quality assessment
The studies varied in quality. Potential biases due to threats to
independent outcome assessment were present in two studies
[2,14], verification bias in two [2,7], and two were presented only
as abstracts [14,15]. Five definitions of febrile neutropenia were
used, with five definitions of fever and two of neutropenia.
However, all definitions were clinically similar, with variation was
mainly in the duration of time for a lower temperature to be
considered ‘prolonged’.
New CDR derivations
Five studies attempted to derive at least one CDR. Four studies
examined rules to predict significant medical complications; a
group of outcomes generally encompassing death, intensive care
admission, significant bacterial or fungal infection, and need for
organ support such as supplemental oxygen, inotropes or dialysis
[7,14,16,17]. Two examined rules to predict bacteraemia [16,18],
and one intensive care admission [15]. In one case a clear CDR
could not be assessed [15]. The CDR used data from the initial/
admission assessment, or from a later assessment after approxi-
mately 24 hours of observation. The new CDR generally had high
sensitivity for the chosen outcome at the expense of poor specificity
(see Table 2) and considered patient-disease, patient-episode and
laboratory factors. Considerable imprecision in the estimates was
seen, due mainly to the small numbers in individual studies (fewer
than 350 patients).
The newly derived CDR were subject to validation by internal
statistical means (cross-validation) or in one alternative data set (see
Table 3). In all except one case [15], multivariable regression
analysis was used to build the model. One rule was built with a
classification and regression tree (CART) approach [15].
Validation of CDR
Four studies [2,7,19,20] were explicit in undertaking validations
of 9 previously described CDR. These universally demonstrated
poorer discriminatory ability when tested in alternative data sets
(see Table 3). The geographical settings for validations of the rules
varied from those where the rule had been derived.
Synthesis of CDR accuracy
Meta-analysis was undertaken for two CDR; the ‘‘Klaassen’’
rule and the ‘‘Ammann’’ rule. Two further CDR, the PINDA rule
and the ‘‘Alexander’’ rule, have not been subject to meta-analysis
as the results are too heterogeneous, these results are presented
graphically. Two further CDR, the Rondellini rule and the
SPOG2003 rule, have been assessed in two datasets, too few to
perform meaningful meta-analysis. No data were available to
update the three-stratum ‘‘Rackoff’’ rule meta-analysis of the
previous study [3].
The ‘‘Klaassen’’ rule is based on a single feature: an absolute
monocyte count of greater than 100/mm
3 to predict patients less
likely to have significant infection. Data were pooled from 4 studies
from the previous review [21,22,23,24] and two new sources
[7,20]. The results of this analysis give a pooled average sensitivity
of 88% (95% CI 84 to 91%) and specificity of 36% (95% CI 27 to
45%), see Figure 2.
The ‘‘Ammann’’ rule describes patients at low risk of significant
bacterial infection as from weighted factors including: bone
marrow involvement, clinical signs of viral infection, serum C-
reactive protein (CRP) level, leukocyte count, presence of a central
venous catheter, high haemoglobin level, and diagnosis of pre-B-
cell leukaemia (see Table 1 for details). Three studies provide data
to test this rule [7,18,20]. The pooled average sensitivity was 98%
(95%CI 91 to 99%) but pooled average specificity only 13% (95%
CI 8% to 21%), see Figure 3.
The ‘‘Alexander’’ rule examined adverse clinical consequences,
using a combination of clinical features which predict prolonged
neutropenia, and significant co-morbidities at presentation. This
rule was assessed by two further studies [2,18]. There was marked
heterogeneity in the results of these three studies (see Figure 4).
When used at reassessment after 48 hrs of hospitalisation, there
was marked improvement in the discriminatory ability of the rule
[2] (sensitivity=100%, specificity=39%).
The PINDA rule again describes patients at low risk of
significant bacterial infection as from weighted factors including
laboratory and chemotherapy related parameters. This has been
examined in two studies from the Santolya group [25,26] and by
two validations from European centres [7,20]. There was marked
heterogeneity (see Figure 5), potentially explained through
geographical variation: the rule worked well applied in the
population in Chile, but failed to differentiate patients in French
and Swiss/German studies.
The rule of Rondellini [27] is a weighted score of clinical and
haematological parameters (see Table 1 for details) and was
assessed in two validation datasets. These demonstrated a
sensitivity of 84% [7] and 62% [20] and both estimated specificity
at 43%.
The SPOG2003 is a weighted score of haematological
parameters with intensity of chemotherapy. It is applied after 8–
24 hours of hospitalisation. This model was shown to have a
sensitivity 92% and specificity of 45% [7]. A validation of this
model demonstrated poorer sensitivity (82%) and slightly better
specificity (57%) [19].
Discussion
This update systematic review builds on previous work to bring
our knowledge of currently developed clinical decision rules for
risk stratification in paediatric febrile neutropenia up to date. Now
nine further models have been described, bringing the total to 25,
Meta-Analysis of Prediction Rules in Paediatric FN
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Patient and disease
related factors Episode specific factors Rule formulation Outcome Inclusion criteria Exclusion criteria
Klaassen [24] None Absolute
monocyte count
Absolutely monocyte
count .100/
mm3=low risk of
bacteraemia
Significant
bacterial infection
ANC ,500cells/mm
3
or #1000cells/mm
3
and falling.
Temperature
.38.0uC $2
occasions in $12 h,
or once .38.5uC, or
localised infection
New malignant
diagnosis; bone
marrow or stem-cell
transplantation in
preceding 6 months.
Another medical
condition that
independently
required inpatient
observation.
Interstitial infiltrate or
lobar consolidation
on chest x-ray
Alexander [28] AML, Burkitts
lymphoma, induction
ALL, progressive
disease, relapsed with
marrow involvement
Hypotension, tachypnea/
hypoxia ,94%, new CXR
changes, altered mental
status, severe mucositis,
vomiting or abdominal
pain, focal infection, other
clinical reason for
in-patient treatment
Absence of any risk
factor=low risk of
serious medical
complication
Significant adverse
outcome
ANC #500/mm
3,
temperature .38.5uC.
Outpatient status.
Post stem cell
transplant
Rondinelli [27] 2 points for central
venous catheter,
1 point for
age .5 years
4.5 points for clinical
site of infection,
2.5 points for no URTI,
1 point each for fever
.38.5uC, hemoglobin
#7 g/dL
Total score
,6=low risk
of serious infectious
complication
Serious infectious
compllications
ANC ,500cells/mm
3
or #1000cells/mm
3
and falling,
temperature
$37.8uC $3
occasions in $24 h,
or once .38.0uC. First
episode per patient
(new or relapsed
disease)
Second or
subsequent episode.
Episodes in
progressive disease
(,6 m from between
completing therapy
and relapse). History
of BMT
PINDA [26] Relapsed leukaemia,
chemotherapy within 7
days of episode
CRP $90 mg/dL,
hypotension,
platelets #50 G/L
Zero risk factors
or only low platelets
or only ,7 days from
chemotherapy=low risk
of invasive bacterial
infection
Invasive bacterial
infection
ANC #500cells/mm
3,
axillary temperature
$38.0uC $2 occasions
1 h apart, or once
$38.5uC
Not reported
Ammann [32] Bone marrow
involvement, central
venous catheter,
pre-B-cell leukemia
Absence of clinical
signs of viral infection,
CRP .50 mg/dL, white
blood cell count
,0.5 G/L, hemoglobin
.10 g/dL
Three or fewer risk
factors=low risk of
significant infection
Significant infection Age 1–18 y, episode
following non-
myleoablative
chemotherapy,
temperature .38.5uCo r
.38uC for .2 h, and
ANC ,500 cells/mm
3
High dose
chemotherapy
SPOG (Adverse
events rule) [7]
Applied after 24 hours:
4 points for
chemotherapy more
intensive than ALL
maintenance
Applied after 24 hours:
5 points for hemoglobin
.90 g/L, 3 points each
for white blood cell count
,0.3 G/L, platelet
,50 G/L, any adverse
event occurred
Total score
,9=low risk
of adverse
FN outcome
Significant adverse
outcome
Age 1–18 y, episode
following non-
myleoablative
chemotherapy,
temperature .38.5uCo r
.38uC for .2 h, and
ANC ,500 cells/mm
3
High dose
chemotherapy
SPOG (Bacteraemia
rule) [18]
None Applied after 24 hours:
shaking chills ever
observed, haemoglobin
.90 g/L, platelet
,50 G/L, any other
need for IP treatment
No risk factors=
low risk of
bacteraemia
presenting after
24 hours
Late bacteraemia
(.24 h)
Age 1–18 y, episode
following non-
myleoablative
chemotherapy,
temperature .38.5uCo r
.38uC for .2 h, and
ANC ,500 cells/mm
3
High dose
chemotherapy
Hakim [16] Score from cancer
diagnosis: AML=20,
ALL/lymphoma=7,
Solids=0
Clinical presentation
of serious unwell or
toxic=14, fever at
presentation:
$39uC=11,
ANC ,100/mm3=
10 points
Total score ,24=
low risk of serious
infection or sepsis
Serious infection
or sepsis
Outpatient,
temperature
.38.3uCo r.38uCf o r
.1 h, and ANC ,500
cells/mm
3
Inpatients, stem cell
transplant recipients
Meta-Analysis of Prediction Rules in Paediatric FN
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Patient and disease
related factors Episode specific factors Rule formulation Outcome Inclusion criteria Exclusion criteria
Hakim [16] Score from cancer
diagnosis: AML=11,
others=0. Relapsed
disease=11.
Non-white patient=8
Clinical presentation of
serious unwell or
toxic=20
Total score ,20=low
risk of any medical
complication
Any medical
complication
Outpatient,
temperature
.38.3uCo r.38uC
for .1 h, and ANC
,500 cells/mm
3
Inpatients, stem cell
transplant recipients
Delebarre [14]
(abstract only)
1 point for
hematological
malignancy,
chemotherapy at
high-risk of
prolonged
neutropenia,
1 point for clinical
signs of local infection,
fever .39uC, white cell
count ,500/mm3 or
monocytes ,100/mm3
and procalcitonin
.0.3 ng/ml. TWO
points for severe sepsis.
High risk .1 point. Severe infection Unclear Unclear
Mian [15] (abstract
only)
No clear rule – uses
postive blood
culture result and
raised CRP
No clear rule Intensive care
admission
Unclear Unclear
Badiei [17] Platelets ,20 g/dL,
temperature $39uC, ANC
,100/mm3, mucositis,
abnormal CXR on
presentation
Risk of infection greater
with more risk factors:
no single threshold
applied
Life threatening
infection
Outpatient,
temperature
.38.5uCo r
.38uC for .1 h, and
ANC ,500 cells/mm3
BMT, Fever with new
diagnosis, inpatient
status
AML=acute myeloid leukaemia; ANC=Absolute neutrophil count; BMT=bone marrow transplant; CXR=chest radiograph; CRP=C-reactive protein; PINDA=Programa
Infantil Nacional de Drogas Antineopla ´sticas; SPOG=Swiss Pediatric Oncology Group; URTI=upper respiratory tract infection.
doi:10.1371/journal.pone.0038300.t001
Table 2. Diagnostic test accuracy of newly described CDR.
Number
of patients
Number
of
episodes
Age of
patients Outcome
Number
with poor
outcome
Proportion
in low risk
group Sensitivity Specificity
Hakim [16] 332 332 Median 6 yrs,
range 2.4
months
to 21.6 years
Serious infection
or sepsis
47 69% 74.5% (95%
CI 60.5%
to 84.7%)
76.4% (95% CI
71.1% to 81.1%)
Medical
complications
40 63.7% 77.5% (95%
CI 62.5% to 87.7%)
69.5% (95% CI
63.9% to 74.5%)
Delebarre [14]
(abstract only)
146 316 Mean age
8 years,
range 0.5 yrs to
17.5 yrs
70 20.6% 98.6% (95% CI
92.3% to 99.7%)
26% (95% CI
20.9% to 31.8%)
Badiei [17],
Threshold
value: 0
risk factors
68 120 Mean 5.9 years Life threatening
infection
35 29.2% 97.1% (95% CI
85.5% to 99.5%)
40% (95% CI
30.2% to 50.6%)
1 risk factor 35 64.2% 71.4% (95% CI
54.9% to 83.7%)
78.8% (95% CI
69% to 86.2%)
2 risk factors 35 75% 62.9% (95% CI
46.3% to 76.8%)
90.6% (95% CI
82.5% to 95.2%)
3 risk factors 35 85% 40% (95% CI
25.6% to 56.4%)
95.3% (95% CI
88.5% to 98.2%)
4 risk factors 35 98.3% 5.7% (95% CI
1.6% to 18.6%)
100% (95% CI
95.7% to 100%)
SPOG [7]
(Adverse
events rule)
206 423 6.9 years
(IQR 3.8
years to
11.6 years)
Serious adverse
medical outcome
122 35% 92% (IQR 91%
to 93%,
range 90%
to 98%)
45% (IQR, 38%
to 49%, range
12% to 57%)
SPOG [18]
(Bacteraemia rule)
Late bacteraemia 67 36% 93% (IQR 91%
to 97%)
41% (IQR 21%
to 45%)
CI=confidence intervals; IQR=interquartile range.
doi:10.1371/journal.pone.0038300.t002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e38300and have included 10,000 episodes. It remains the case that no one
rule is clearly better than any other, but we are now more clearly
aware of the limitations of CDR which have not been subject to
temporal and geographical validation.
The majority of CDR in this review focus upon defining a group
at ‘low risk’ of complications. These rules once again have clinical
and physiological similarities. The dominant themes are of a
relationship between underlying diagnosis, chemotherapeutic
regime, and clinical and laboratory parameters at the outset of
T
a
b
l
e
3
.
C
o
n
t
.
R
u
l
e
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
N
u
m
b
e
r
o
f
e
p
i
s
o
d
e
s
A
g
e
o
f
p
a
t
i
e
n
t
s
O
u
t
c
o
m
e
P
r
o
p
o
r
t
i
o
n
i
n
l
o
w
r
i
s
k
g
r
o
u
p
S
e
n
s
i
t
i
v
i
t
y
S
p
e
c
i
f
i
c
i
t
y
S
P
O
G
[
7
]
(
A
d
v
e
r
s
e
e
v
e
n
t
s
r
u
l
e
d
e
r
i
v
a
t
i
o
n
)
2
0
6
4
2
3
6
.
9
y
e
a
r
s
(
I
Q
R
3
.
8
y
e
a
r
s
t
o
1
1
.
6
y
e
a
r
s
)
S
e
r
i
o
u
s
a
d
v
e
r
s
e
m
e
d
i
c
a
l
o
u
t
c
o
m
e
3
5
%
9
2
%
(
I
Q
R
9
1
%
t
o
9
3
%
,
r
a
n
g
e
9
0
%
t
o
9
8
%
)
4
5
%
(
I
Q
R
,
3
8
%
t
o
4
9
%
,
r
a
n
g
e
1
2
%
t
o
5
7
%
)
M
i
e
d
e
i
m
a
[
1
9
]
1
1
0
2
1
0
M
e
d
i
a
n
6
.
6
y
e
a
r
s
(
I
Q
R
4
.
3
y
e
a
r
s
t
o
1
0
.
8
y
e
a
r
s
)
S
e
r
i
o
u
s
a
d
v
e
r
s
e
m
e
d
i
c
a
l
o
u
t
c
o
m
e
5
0
%
8
2
%
(
9
5
%
C
I
,
7
7
%
t
o
8
7
%
5
7
%
(
9
5
%
C
I
,
5
0
%
t
o
6
4
%
)
R
o
n
d
i
n
e
l
l
i
R
u
l
e
[
2
7
]
(
n
o
d
e
r
i
v
a
t
i
o
n
d
a
t
a
)
M
a
c
h
e
r
[
2
0
]
1
6
7
3
7
7
M
e
d
i
a
n
6
y
,
r
a
n
g
e
7
m
t
o
1
9
y
S
e
v
e
r
e
b
a
c
t
e
r
i
a
l
i
n
f
e
c
t
i
o
n
N
/
A
6
2
%
(
3
6
–
8
2
)
4
3
%
(
3
4
–
5
2
)
S
P
O
G
[
7
]
2
0
6
4
2
3
6
.
9
y
e
a
r
s
(
I
Q
R
3
.
8
y
e
a
r
s
t
o
1
1
.
6
y
e
a
r
s
)
S
e
v
e
r
e
b
a
c
t
e
r
i
a
l
i
n
f
e
c
t
i
o
n
3
5
%
8
4
.
4
%
(
9
5
%
C
I
7
7
%
t
o
8
9
.
8
%
)
4
3
.
2
%
(
9
5
%
C
I
3
7
.
7
%
t
o
4
8
.
8
%
)
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
8
3
0
0
.
t
0
0
3
Figure 2. Individual and pooled diagnostic test accuracy of
‘Klaassen’ rule. The ROC space plots show each study estimates of
sensitivity and specificity as a marker at the point estimate, with 95%
confidence intervals demonstrated by lines. In reading such graphs,
tests with a better discriminatory ability fall in the top left corner of the
plot, and non-discriminatory tests fall on a 45u line between the bottom
left and top right. The light lines and circles represent individual studies,
with the darker dashed lines showing the study from which the rule was
derived. The dark circle is the pooled estimate of sensitivity and
specificity, and the dashed ellipse represents the bivariate 95%
confidence intervals of this result.
doi:10.1371/journal.pone.0038300.g002
Figure 3. Individual and pooled diagnostic test accuracy of
‘Ammann’ rule. The ROC space plots here has the light lines and
circles represent individual studies, with the darker dashed lines
showing the study from which the rule was derived, and the heavy
dark lines the pooled estimate of sensitivity and specificity, with the
univariate 95% confidence intervals.
doi:10.1371/journal.pone.0038300.g003
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demonstration that undertaking risk stratification at 24–48 hours
after the onset of the episode leads to much greater discrimination,
as many occult infections will have declared in this period.
Two rules have shown relative consistency of results. These are
the simplest stratification of patients using the criteria of absolute
monocyte count .100/mm
3 to define a low risk group [24]. This
has a pooled average sensitivity of 88% (95% CI 84 to 91%) and
specificity of 36% (95% CI 27 to 45%), and if we assume serious
infectious events occur in 30% of the group, the low-risk group has
a 9% risk of serious infection, and accounts for approximately 29%
of the total population. The high risk group has a 37% risk of
infectious complications.
The Ammann 2003 rule [7] has much better sensitivity
(estimated at 98%), leading to a risk of serious infectious
complications in around 5% cases, but would only class 9% of
patients as low risk, making it of little practical use.
Other further rules have shown marked heterogeneity: the
Alexander rule [28] and the PINDA rule. The data support the
use of the PINDA rule in Chile, where it has been successfully
validated [25], but do not support its use in Europe. A similar
situation exists with the Brazilian rule [27] which again was not
successfully validated in European data sets. The Alexander rule
did not successfully differentiate patients at admission in the UK
and Europe, but its use at a 48 hour reassessment was associated
with successful reductions in hospital stay. A further, newer, rule
from the SPROG group requires more validation before a decision
can be made on its usefulness.
These findings, that validation of CDR may be poor in
comparison to derivation, and that geographical variation may
mean CDR fail to work universally, have important clinical
implications. There is a wealth of examples in the statistical and
methodological literature regarding the over-optimism of newly
derived CDR [29,30]. The core concept is that rules derived from
one dataset fit the idiosyncrasies and anomalies of the data
collected, rather than reflecting the predictive power in the whole
population of children experiencing FNP. However, these
frequently equation-laden papers are uncommonly read by
clinicians, and the complex approaches suggested to ‘shrinking’
the CDR values to increase their reproducibility are tricky to
understand and to implement. The finding of geographical
variation is potentially through different interpretations of similar
findings; for example, how ‘‘unwell’’ should a child appear before
they fall into this diagnostic category? There may also be subtle
differences in the regimes used, as an example the use of steroid
pulses in maintenance treatment for acute lymphoblastic leukae-
mia varies across Europe, and this may affect the CDR
discriminatory ability.
This review has demonstrated there is an increasingly wide
range of rules mainly for the prediction of an absence of adverse
outcomes during episodes of febrile neutropenia in children,
despite the existence of at least sixteen other applicable CDR [3].
Six rules have been subject to further verification, each
demonstrating a variable degree of over-optimism in the original
reports when the CDR is applied in different settings. The small
size of these reports, with low ratios of events per variable
examined may explain some of the variability in factors selected
and poor reproducibility, as may undefined aspects of geograph-
ical differences between populations.
The practical application of these CDR requires it to be
appropriate to the healthcare setting, and validated in the setting
in which it is to be used. There remains a need for further research
to reduce uncertainty around the efficiency of CDR, and
potentially generate a very robust model on the basis of a much
larger dataset, with well over 20 events per variable under
examination. Importantly, rules should also identify a group at the
highest risks of complications, to concentrate hopefully lifesaving
early sepsis interventions in this group [31]. This project is already
underway, with the PICNICC collaboration having collected data
on around 5000 episodes of febrile neutropenia from 18
collaborating groups across North & South America, Europe
and Asia.
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Figure 4. Individual diagnostic test accuracy of ‘Alexander’
rule. The light lines and circles represent individual studies, with the
darker dashed lines showing the study from which the rule was derived.
doi:10.1371/journal.pone.0038300.g004
Figure 5. Individual and pooled diagnostic test accuracy of
‘PINDA’ rule. The light lines and circles represent individual studies,
with the darker dashed lines showing the study from which the rule was
derived.
doi:10.1371/journal.pone.0038300.g005
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